Feasibility of intravaginal artesunate as an adjuvant HPV & cervical precancer treatment among women living with HIV in Kenya: Study protocol for a phase II clinical Trial
Authors:
Preprint
Abstract
Background Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), who account for 90% of deaths from the disease. Human papillomavirus (HPV) is responsible for 99% of cervical cancer cases. Women living with HIV (WLWH) have a higher risk of persistent HPV infection and a greater likelihood of developing cervical cancer. Prevention of cervical cancer requires effective screening and precancer treatment programs. In LMICs, the common treatment method for cervical precancer is thermal ablation. However, for WLWH, thermal ablation is associated with high rates of persistent HPV infection following treatment, a key risk factor for precancer recurrence. Adjuvant topical treatments with cytotoxic or antiviral properties may reduce HPV persistence HPV following ablation. Preclinical and early-phase clinical trials indicate that topical artesunate is active against HPV-associated anogenital lesions, including cervical precancer, and can induce HPV clearance. Consequently, intravaginal artesunate may improve HPV clearance following thermal ablation, although no clinical trials have investigated this. Methods We are conducting a phase II, double-blind, randomized, placebo-controlled trial among 120 HIV seropositive women in Kenya to investigate the feasibility of self-administered intravaginal artesunate pessaries as adjuvant therapy following thermal ablation treatment for cervical precancer. The primary outcome is type-specific HPV clearance six months after randomization. Secondary outcomes are safety, adherence, acceptability, uptake, and retention. Participants will use self-administered artesunate pessaries starting at least 4 weeks following ablation, on weeks 1,3,5 with alternating drug-free weeks, with a follow-up period extending up to 24 weeks after randomization. Discussion High rates of persistent HPV infection in WLWH is a key limitation of thermal ablation, the most accessible cervical precancer treatment in LMICs. This trial will investigate the feasibility of repurposing topical artesunate as an adjuvant therapy to improve HPV clearance following thermal ablation in WLWH. Trial Registration ClinicalTrials.gov identifier: daKeywords
All Related Versions
- Published version: Cancer Control, 32.
This publication has 32 references indexed in Scilit:
- Role of Reserve Cells in Metaplasia and the Development of Human Papillomavirus–Associated High-Grade Squamous Intraepithelial Lesions at the Cervical Transformation ZoneLaboratory Investigation, 2025
- Efficacy of thermal ablation for treatment of biopsy‐confirmed high‐grade cervical precancer among women living with HIV in KenyaInternational Journal of Cancer, 2023
- Can we increase the cervical cancer screening interval with an HPV test for women living with HIV? Results of a cohort study from Maharashtra, IndiaInternational Journal of Cancer, 2022
- Human Papillomavirus Persistence and Association With Recurrent Cervical Intraepithelial Neoplasia After Cryotherapy vs Loop Electrosurgical Excision Procedure Among HIV-Positive WomenJAMA Oncology, 2021
- A first-in-human proof-of-concept trial of intravaginal artesunate to treat cervical intraepithelial neoplasia 2/3 (CIN2/3)Gynecologic Oncology, 2020
- Thermal ablation versus cryotherapy or loop excision to treat women positive for cervical precancer on visual inspection with acetic acid test: pilot phase of a randomised controlled trialThe Lancet Oncology, 2020
- Worthy of further consideration: An updated meta-analysis to address the feasibility, acceptability, safety and efficacy of thermal ablation in the treatment of cervical cancer precursor lesionsPreventive Medicine, 2019
- Cervical cancer screening through human papillomavirus testing in community health campaigns versus health facilities in rural western KenyaInternational Journal of Gynecology & Obstetrics, 2018
- Treatment of cervical intraepithelial lesionsInternational Journal of Gynecology & Obstetrics, 2017
- HPV testing in the context of post-treatment follow up (test of cure)Journal of Clinical Virology, 2016